We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Potentially First Preoperative Breast Cancer Drug Gets Positive FDA Review
Potentially First Preoperative Breast Cancer Drug Gets Positive FDA Review
September 10, 2013
FDA reviewers say data submitted by Genentech in support of its sBLA for Perjeta as preoperative breast cancer drug show significant improvement for breast cancer patients and sufficient safety.